A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

In patients with relapsing–remitting multiple sclerosis, oral fingolimod reduced the rates of relapse and disability progression, as compared with placebo. Adverse events included bradycardia, atrioventricular conduction block, macular edema, elevations in liver-enzyme levels, and mild hypertension.


Leave a Reply

%d bloggers like this: